Plain-English translation of NCT07619820 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called (clazakizumab) in people with end-stage kidney disease who depend on dialysis. The study will measure how the medication moves through your body and whether it is safe when given regularly over several months. About 24 people in China will participate, with roughly half receiving the medication and half receiving a placebo (a non-active look-alike injection).
End-stage kidney disease is a serious condition, and doctors are looking for new treatment options to help manage inflammation and improve outcomes for patients on dialysis. This trial is a first step in testing whether this medication could be a safe and effective option for this population.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will visit the study center once every 4 weeks for 20 weeks total. At each visit, you will receive a slow intravenous injection (either the new medication or placebo—you won't know which). The study team will take blood samples to measure how the medication moves through your body and monitor your safety. You will be asked questions about how you are feeling and any side effects you may experience.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
CSL Behring
Enrollment target
~24 participants
Started
June 2026
Primary completion
August 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Trial Registration Coordinator
CSL Behring
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.